Weekly Digest – June 2026 Weekly Digest – June 2026 15 June 2026: Lonza grants Antharis exclusive license to develop dual-payload ADCs for GI cancers Antharis Therapeutics has entered into an exclusive, target-specific licensing agreement with Lonza to develop next-generation […]
Weekly Digest – June 2026 Weekly Digest – June 2026 09 June 2026: AmMax Bio licenses antibody-drug conjugate technology for Hematological cancers from Lonza AmMax Bio has entered into a licensing agreement with Lonza to access its clinically validated antibody-drug […]
Weekly Digest – June 2026 Weekly Digest – June 2026 08 June 2026: Johnson & Johnson to acquire Firefly Bio to expand oncology pipeline with degrader ADC platform Johnson & Johnson has entered into a definitive agreement to acquire Firefly […]
Weekly Digest – June 2026 Weekly Digest – June 2026 04 June 2026: Stipple Bio enters multi-target license agreement with Lonza to advance precision oncology ADC therapies Stipple Bio has strengthened its position in the next wave of ADC innovation […]
Weekly Digest – June 2026 Weekly Digest – June 2026 01 June 2026: Mabion and KriSan Biotech sign letter of intent to explore ADC collaboration supporting strategic ambitions advanced Solid tumor study Mabion and KriSan Biotech have signed a Letter […]
Weekly Digest – June 2026 Weekly Digest – June 2026 29 May 2026: Ratio Therapeutics and PharmaLogic expand manufacturing collaboration to support clinical development of [Ac-225]RTX-2358 Ratio Therapeutics and PharmaLogic have expanded their manufacturing collaboration to support the clinical development […]
Weekly Digest – May 2026 Weekly Digest – May 2026 26 May 2026: Adcendo and MSD partner to evaluate ADCE-T02 plus KEYTRUDA in phase 1b advanced Solid tumor study Adcendo has entered a clinical collaboration and supply agreement with MSD […]
Weekly Digest – May 2026 Weekly Digest – May 2026 06 May 2026: HLX43 received PMDA acknowledgment to initiate a global Phase 2/3 trial in squamous Non-Small Cell Lung Cancer Henlius has achieved a key milestone for its anti-PD-L1 ADC […]
Weekly Digest – April 2026 Weekly Digest – April 2026 30 March 2026: Zymeworks receives U.S. FDA Fast Track Designation for ZW191, an FRα-targeting ADC Zymeworks’ FRα-targeting ADC, ZW191, has received FDA Fast Track designation for patients with advanced or […]
Weekly Digest – April 2026 Weekly Digest – April 2026 01 April 2026: RemeGen’s dual-antibody ADC RC288 for the treatment of advanced malignant solid tumors has been officially approved for clinical trials RemeGen’s dual-target ADC, RC288, has received clinical trial […]
